Emactuzumab (SynOx Therapeutics) is the name of a monoclonal antibody currently in trial for TGCT. Monoclonal antibodies are engineered protein that bind to one substance, in this case CSF1. Once it binds, the CSF1 cannot interact with surrounding cells, reducing growth and symptoms of disease.
It is a Phase 3 randomized study, meaning the optimal dose is known and the effectiveness is being investigated. The Phase 3 trial is known as TANGENT.
Published data from the Phase 1 trial suggests it has an improved tolerability profile and remains effective at shrinking TGCT in 71% of patients with a robust response for up to 800 study days (1). The most common side effects include itching (70%), lack of energy (62%), facial swelling (49%), extremity swelling (44%), eyelid swelling (37%), headaches (30%), nausea (29%), rash (29%), fatigue (24%) among others.
It is currently recruiting at global clinical locations, including the US, Europe, and the UK. Emactuzumab or a saline infusion (placebo) is given intravenously (IV) every 2 weeks for a total of 5 times. Patients will be observed for 3 additional months and following 24 weeks, patients tumor shrinkage, range of motion, and patient reported pain, stiffness, and function will be reviewed.